Irras AB is Sweden- based medical device company primarily engaged in develops and commercializes solutions that are designed to transform neurocritical care. Company focus on neurosurgical procedures, where excess cerebrospinal fluid (CSF) or toxic blood byproducts often need to be emergently drained and intracranial pressure (ICP) needs to be closely regulated.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

Market Cap	182M 18.43M 16.08M 15.23M 13.78M 25.8M 1.77B 26.03M 70.08M 899M 69.25M 67.71M 2.9B	P/E 2023	-0.73x	P/E 2024	-1.89x
Enterprise Value	396M 40.12M 34.99M 33.14M 29.99M 56.15M 3.85B 56.64M 153M 1.96B 151M 147M 6.32B	EV / Sales 2023	5.26x	EV / Sales 2024	6.82x
Free-Float	3.55%	Yield 2023 *	-	Yield 2024	-

25-06-27	IRRAS AB Reports Earnings Results for the Full Year Ended December 31, 2024	CI
24-06-17	IRRAS AB Reports Earnings Results for the Full Year Ended December 31, 2023	CI
23-11-03	Irras has today its last day of trading on Nasdaq Stockholm before delisting	FW
23-10-24	IRRAS AB(OM:IRRAS) dropped from OMX Nordic All-Share Index	CI
23-10-24	IRRAS AB(OM:IRRAS) dropped from OMX Nordic Small Cap Index	CI
23-10-23	Irras Obtains Nasdaq Approval for Delisting in Stockholm	MT
23-10-20	Irras delisted from Nasdaq Stockholm with last trading day on November 3	FW
23-10-20	Sweden's Irras Files for Delisting as Privatization Nears Completion	MT
23-10-19	IR Holding Bidco calls for compulsory acquisition in Irras - applies for delisting	FW
23-10-16	Irras Obtains Extension for SEK20 Million Loan	MT
23-10-15	Irras extends SEK 20 million short-term loan	FW
23-10-02	Bidder controls 87.9 percent of the shares in Irras after completion of takeover bid	FW
23-09-18	Set-off issue only realistic option to avoid insolvency situation - Irra Board	FW

23-06-30	Bid for Irras below historical median premium - but also high risk of more fundraising - Afv(R)	FW
23-06-30	Bid for Irras below historical median premium - but also high risk of more fundraising - Afv	FW
23-05-22	Irra's Q1 sales below expectations - Redeye predicts new share issue and halves fair value	FW
23-05-21	Redeye lowers motivated value for Irras to SEK 0.15 (0.30)	FW
23-02-20	Redeye reiterates motivated value for Irras, but predicts capital raising this year	FW

23-10-20	IRRAS's application for delisting has been approved and the Board of Directors has resolved not to publish the interim report for the third quarter of 2023	AQ
23-10-19	NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING OF IRRAS AB	AQ
23-10-19	IR Holding Bidco Inc. requests compulsory buy-out and IRRAS applies for delisting	AQ
23-10-16	IRRAS publishes prospectus	AQ
23-10-15	IRRAS has extended maturity date for its SEK 20 million short-term loan	AQ

Manager	Title	Age	Since
Will Martin CEO	Chief Executive Officer	51	2021-06-30
Griffen Stapp DFI	Director of Finance/CFO	40	2021-06-16
Sten Gustafsson IRC	Investor Relations Contact	-	2021-03-08

IRRAS AB Stock OTC Markets

Stocks

IRRA.F

SE0008321202

Medical Equipment, Supplies & Distribution

Valuation: IRRAS AB

Latest news: IRRAS AB

Analysts' recommendations: IRRAS AB

Press Releases: IRRAS AB

Quotes and Performance

Managers and Directors: IRRAS AB

Medical Devices & Implants

Financials

Company Profile

Director	Title	Age	Since
Kleanthis Xanthopoulos BRD	Director/Board Member	68	2015-05-31
Marios Fotiadis CHM	Chairman	53	2020-08-17
Inger Gunnel Anita Tollstadius BRD	Director/Board Member	71	2017-08-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IRRAS AB	-15.36%	-27.68%	-	-	16.9M
STRYKER CORPORATION	+1.16%	+3.01%	-24.49%	-2.74%	108B
SMITH & NEPHEW PLC	+0.43%	+1.56%	-24.77%	-2.11%	11.77B
GLAUKOS CORPORATION	-4.78%	-11.66%	+102.72%	+117.61%	10.12B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	+0.57%	-4.58%	-54.22%	-71.49%	3.97B
DOUBLE MEDICAL TECHNOLOGY INC.	-1.25%	-5.64%	-29.26%	+21.67%	2.36B
INSPIRE MEDICAL SYSTEMS, INC.	-2.48%	+17.07%	-9.90%	-65.51%	2.16B
INSIGHT LIFETECH CO., LTD.	0.00%	-5.48%	-	-	1.82B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	+1.19%	-3.04%	-21.91%	-30.15%	1.5B
Average	-2.35%	+1.57%	-8.83%	-4.67%	17.71B
Weighted average by Cap.	+0.07%	+1.23%	-15.98%	+3.23%

	2023	2024
Net sales	42.88M 4.35M 3.79M 3.59M 3.25M 6.09M 417M 6.14M 16.53M 212M 16.34M 15.97M 685M	57.98M 5.88M 5.13M 4.86M 4.4M 8.23M 564M 8.3M 22.36M 287M 22.09M 21.6M 926M
Net income	-209M -21.19M -18.48M -17.5M -15.84M -29.65M -2.03B -29.91M -80.54M -1.03B -79.58M -77.81M -3.34B	-95.98M -9.74M -8.49M -8.04M -7.28M -13.62M -934M -13.74M -37.01M -475M -36.57M -35.76M -1.53B
Net Debt	43.85M 4.45M 3.88M 3.67M 3.32M 6.22M 427M 6.28M 16.91M 217M 16.71M 16.33M 700M	214M 21.68M 18.91M 17.91M 16.21M 30.35M 2.08B 30.61M 82.44M 1.06B 81.45M 79.64M 3.41B